Doris Benbrook to Angiogenesis Inhibitors
This is a "connection" page, showing publications Doris Benbrook has written about Angiogenesis Inhibitors.
Connection Strength
1.199
-
A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Nov; 127(2):356-61.
Score: 0.381
-
Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Invest New Drugs. 2009 Aug; 27(4):304-18.
Score: 0.293
-
A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol. 2007 Sep; 106(3):596-603.
Score: 0.269
-
Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol Oncol. 2014 Apr; 133(1):11-5.
Score: 0.107
-
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50.
Score: 0.084
-
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 May; 105(2):508-16.
Score: 0.065